ClinicalTrials.gg
CompletedNCT04753840Updated Nov 10, 2026

Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Hypertension

An interventional study of CRIC and MFT in Hypertension, sponsored by Henan Institute of Cardiovascular Epidemiology. Completed at 5 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Henan Institute of Cardiovascular Epidemiology · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedStart date moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Enrollment
67th of 308
600 · median 253
Started
2023
with 28 others
No phase
146 of 410
56 open now
Registered
199th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 67th largest by enrollment of the 308 interventional ones that give a count, is one of 29 that started in 2023, is one of 146 with no phase, and was the 199th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

Hypertension is a major risk factor for cardiovascular disease. Remote ischemic conditioning (RIC) and mindfulness-based interventions are non-pharmacological approaches that may help reduce blood pressure through different physiological mechanisms. However, evidence regarding their long-term effects and potential combined benefits remains limited.

This multicenter, randomized, sham-controlled clinical trial evaluated the effects of RIC, mindfulness-based intervention, and their combination on home blood pressure in patients with hypertension. A total of 600 participants were randomly assigned to four groups in a 2×2 factorial design. The interventions were administered twice daily for 12 months. The primary objective was to assess changes in home systolic blood pressure after 12 months of intervention. Secondary objectives included evaluating diastolic blood pressure, the time course of blood pressure changes, treatment response, and safety.

Read the detailed description

This was a multicenter, randomized, sham-controlled, 2×2 factorial clinical trial conducted at five hospitals in China. A total of 600 patients with essential hypertension were enrolled between September 2023 and August 2024 and randomly assigned in a 1:1:1:1 ratio to four intervention groups:

  1. Control group: sham remote ischemic conditioning (RIC) combined with nature-sound audio.
  2. RIC group: active RIC combined with nature-sound audio.
  3. Mindfulness group: sham RIC combined with guided mindfulness intervention.
  4. Combination group: active RIC combined with guided mindfulness intervention.

Active RIC consisted of three cycles of upper-arm cuff inflation for 6 minutes followed by deflation for 4 minutes, with a total session duration of 30 minutes. Inflation pressure was individualized according to baseline systolic blood pressure using predefined pressure increments. Sham RIC followed the same inflation-deflation schedule with a cuff pressure of 60 mmHg.

The mindfulness intervention consisted of standardized audio-guided mindfulness practice delivered simultaneously with the cuff intervention. The control audio consisted of natural sounds, such as ocean waves, flowing water, and birdsong, without hypertension education or mindfulness instructions. Both interventions were administered twice daily for 12 months.

Home blood pressure was measured repeatedly throughout the study using an automated monitoring system. The primary outcome was the change in pre-intervention home systolic blood pressure from baseline to 12 months. Additional assessments included diastolic blood pressure, longitudinal blood pressure trajectories, blood pressure control and response rates, immediate blood pressure responses, treatment adherence, and adverse events.

Selected circulating biomarkers were also measured in a subset of participants for mechanistic investigations.

The study was designed to assess the independent and combined effects of RIC and mindfulness-based intervention on long-term blood pressure control.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-80 years.
  • Diagnosis of essential hypertension according to established clinical guidelines, with a mean screening home systolic blood pressure (SBP) of 135-179 mmHg and a mean home diastolic blood pressure (DBP) below 105 mmHg.
  • Participants who were either untreated or receiving antihypertensive medication with inadequately controlled blood pressure. For participants receiving antihypertensive medication, drug classes and doses had to remain stable for at least 4 weeks before enrollment, with no planned active adjustment during the study.
  • Completion of at least 2 weeks of twice-daily home blood pressure monitoring during screening, with the mean home SBP remaining within 135-179 mmHg before randomization.
  • Ability and willingness to perform twice-daily home blood pressure monitoring and complete the 12-month intervention and follow-up.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Secondary hypertension of any cause or incomplete screening for secondary causes of hypertension.
  • Cardiovascular or cerebrovascular events within 6 months before enrollment.
  • arrhythmias, including atrial fibrillation or frequent ventricular premature beats, that could interfere with automated blood pressure measurement.
  • Peripheral vascular disease, severe upper-limb vascular insufficiency, or conditions precluding safe cuff inflation, including an arteriovenous fistula in the measurement arm, lymphedema, skin lesions, or upper-limb surgery within the preceding 3 months.
  • Orthostatic hypotension, defined as a systolic blood pressure decrease of at least 20 mmHg on standing or symptomatic orthostatic hypotension.
  • Inter-arm systolic blood pressure difference greater than 15 mmHg.
  • Severe target-organ damage, including estimated (eGFR) below 30 mL/min/1.73 m², (LVEF) below 40%, or (NYHA) functional class III-IV.
  • Poorly controlled diabetes mellitus ( ≥9.0%) or established diabetic autonomic neuropathy.
  • Pregnancy, planned pregnancy, or lactation.
  • Participation in another interventional clinical trial within 30 days before enrollment.
  • Inability to comply with the study protocol because of cognitive impairment, severe psychiatric disorders, or logistical difficulties with follow-up.
  • Confirmed mean screening home DBP ≥105 mmHg on repeat measurement.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    CRIC+MFT

    CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg). MFT:Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.

    Device: CRIC · Behavioral: MFT

  • Experimental
    sham CRIC+MFT

    Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation. MFT: Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.

    Behavioral: MFT · Other: sham CRIC

  • Experimental
    CRIC+sham MFT

    CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg). Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.

    Device: CRIC · Other: sham MFT

  • Placebo comparator
    Sham CRIC+Sham MFT

    Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation. Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.

    Other: sham CRIC · Other: sham MFT

Interventions

  • DeviceCRIC

    Remote Ischemic Conditioning (CRIC): Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).

  • BehavioralMFT

    Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

  • Othersham CRIC

    Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

  • Othersham MFT

    The control audio consisted of standardized recordings of natural sounds, including ocean waves, flowing water, and birdsong, without mindfulness instructions, breathing exercises, or hypertension-related health education. Each audio session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Home Systolic Blood Pressure at 12 Months

    Change in mean pre-intervention home systolic blood pressure (SBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was excluded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention SBP measurements during days 335-364 after randomization. Participants with at least 20 valid measurement sessions during this window were included in the primary endpoint analysis. The outcome was expressed in mmHg.

    Time frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)

Secondary outcomes

  1. Change From Baseline in Home Diastolic Blood Pressure at 12 Months

    Change in mean pre-intervention home diastolic blood pressure (DBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was discarded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention DBP measurements during days 335-364 after randomization. Changes were expressed in mmHg.

    Time frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364)

  2. Change From Baseline in Home Systolic Blood Pressure at Months 1, 3, 6, and 9

    Changes in mean pre-intervention home systolic blood pressure (SBP) from screening baseline at multiple follow-up time points. Home SBP was measured twice daily using an automated device, with the mean of the second and third pre-intervention readings used for each session. Window-mean SBP values were calculated around days 30, 90, 180, and 270 after randomization to characterize the longitudinal blood pressure response to the assigned interventions. Changes were expressed in mmHg.

    Time frame: Baseline and Days 30, 90, 180, and 270 after randomization

  3. Proportion of Participants Achieving a Systolic Blood Pressure Reduction of at Least 5 mmHg

    Proportion of participants achieving a reduction of at least 5 mmHg in mean pre-intervention home systolic blood pressure from screening baseline to the 12-month endpoint window (days 335-364 after randomization). The response rate was calculated as the number of participants meeting this threshold divided by the number of participants with evaluable endpoint data, expressed as a percentage.

    Time frame: Baseline and Month 12 (days 335-364)

  4. Proportion of Participants Achieving Home Blood Pressure Control Below 135/85 mmHg

    Proportion of participants achieving home blood pressure control, defined as a mean pre-intervention home systolic blood pressure below 135 mmHg and a mean pre-intervention home diastolic blood pressure below 85 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.

    Time frame: Month 12 (days 335-364)

  5. Proportion of Participants Achieving Home Blood Pressure Control Below 140/90 mmHg

    Proportion of participants achieving home blood pressure control using a less stringent threshold, defined as a mean pre-intervention home systolic blood pressure below 140 mmHg and a mean pre-intervention home diastolic blood pressure below 90 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.

    Time frame: Month 12 (days 335-364)

  6. Within-Session Change in Home Systolic Blood Pressure

    The immediate blood pressure response was assessed as the difference between post-intervention and pre-intervention home systolic blood pressure within each treatment session. Three consecutive blood pressure measurements were obtained before and after each session, with the first reading excluded and the mean of the remaining two readings used for each time point. The participant-level mean of post-intervention minus pre-intervention SBP differences was calculated across available sessions. Between-group comparisons relative to the double-sham control group were used to estimate the net immediate intervention effect, expressed in mmHg.

    Time frame: Throughout the 12-month intervention period

07

Study locations

5 sites
  • Anyang District Hospital
    Anyang, Henan 455000, China
  • Huaihe Hospital of Henan University
    Kaifeng, Henan 475000, China
  • Yongcheng Central Hospital
    Shangqiu, Henan 476600, China
  • Fuwai central China Cardiovascular hospital
    Zhengzhou, Henan 450008, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, 471000, China
08

References and documents

Publications

  • Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens. 2014 Jul;27(7):918-25. doi: 10.1093/ajh/hpu004. Epub 2014 Mar 13. PubMed 24627443 ↗
  • Moro L, Pedone C, Mondi A, Nunziata E, Antonelli Incalzi R. Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people. Atherosclerosis. 2011 Dec;219(2):750-2. doi: 10.1016/j.atherosclerosis.2011.08.046. Epub 2011 Sep 7. PubMed 21945497 ↗

Individual participant data

Plan to share: No — IPD can be obtained from the researcher upon reasonable request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Aug 2025, 23 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 23 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Jul 2021 → Sep 2023, primary completion Dec 2026 → Aug 2025 and completion Dec 2030 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2021
First posted
Feb 15, 2021
StartActual
Sep 1, 2023was Jul 2021
Primary completionActual
Aug 31, 2025was Dec 2026
CompletionActual
Jan 1, 2026was Dec 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Sites
4 sites added
Show 4 added (4 China)
  • Anyang District Hospital · Anyang, China
  • Huaihe Hospital of Henan University · Kaifeng, China
  • Yongcheng Central Hospital · Shangqiu, China
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
Nov 10, 2026
Start date
Jul 3, 2021→Sep 1, 2023
Nov 10, 2026
Primary completion
Dec 1, 2026→Aug 31, 2025 (actual)
Nov 10, 2026
Study completion
Dec 1, 2030→Jan 1, 2026 (actual)
Nov 10, 2026
Enrollment
400 (estimated)→600 (actual)
Nov 10, 2026
Eligibility
Criteria largely rewritten (23 changes)
What changed in the criteria
Inclusion criteria
  • RemovedDiagnosed patients with mild hypertension (SBP: 140~159mmHg; DBP: 90~99mmHg)
  • AddedAdults aged 18-80 years.
  • AddedDiagnosis of essential hypertension according to established clinical guidelines, with a mean screening home systolic blood pressure (SBP) of 135-179 mmHg and a mean home diastolic blood pressure (DBP) below 105 mmHg.
  • AddedParticipants who were either untreated or receiving antihypertensive medication with inadequately controlled blood pressure. For participants receiving antihypertensive medication, drug classes and doses had to remain stable for at least 4 weeks before enrollment, with no planned active adjustment during the study.
  • AddedCompletion of at least 2 weeks of twice-daily home blood pressure monitoring during screening, with the mean home SBP remaining within 135-179 mmHg before randomization.
  • AddedAbility and willingness to perform twice-daily home blood pressure monitoring and complete the 12-month intervention and follow-up.
  • AddedProvision of written informed consent.
Exclusion criteria
  • RemovedCannot tolerate RIPC
  • RemovedNon-essential hypertension
  • Removedpatients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
  • Removedpatients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
  • AddedSecondary hypertension of any cause or incomplete screening for secondary causes of hypertension.
  • AddedCardiovascular or cerebrovascular events within 6 months before enrollment.
  • AddedClinically significant arrhythmias, including atrial fibrillation or frequent ventricular premature beats, that could interfere with automated blood pressure measurement.
  • AddedPeripheral vascular disease, severe upper-limb vascular insufficiency, or conditions precluding safe cuff inflation, including an arteriovenous fistula in the measurement arm, lymphedema, skin lesions, or upper-limb surgery within the preceding 3 months.
  • AddedOrthostatic hypotension, defined as a systolic blood pressure decrease of at least 20 mmHg on standing or symptomatic orthostatic hypotension.
  • AddedInter-arm systolic blood pressure difference greater than 15 mmHg.
  • AddedSevere target-organ damage, including estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², left ventricular ejection fraction (LVEF) below 40%, or New York Heart Association (NYHA) functional class III-IV.
  • AddedPoorly controlled diabetes mellitus (HbA1c ≥9.0%) or established diabetic autonomic neuropathy.
  • AddedPregnancy, planned pregnancy, or lactation.
  • AddedParticipation in another interventional clinical trial within 30 days before enrollment.
  • AddedInability to comply with the study protocol because of cognitive impairment, severe psychiatric disorders, or logistical difficulties with follow-up.
  • AddedConfirmed mean screening home DBP ≥105 mmHg on repeat measurement.
Nov 10, 2026
Primary outcomes
1 added, 2 removed
What changed in the outcomes
  • AddedChange From Baseline in Home Systolic Blood Pressure at 12 MonthsTime frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)
  • RemovedMean systolic blood pressureTime frame: 3 months
  • RemovedMean diastolic blood pressureTime frame: 3 months
Nov 10, 2026
Secondary outcomes
6 added, 5 removed
What changed in the outcomes
  • AddedChange From Baseline in Home Diastolic Blood Pressure at 12 MonthsTime frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364)
  • AddedChange From Baseline in Home Systolic Blood Pressure at Months 1, 3, 6, and 9Time frame: Baseline and Days 30, 90, 180, and 270 after randomization
  • AddedProportion of Participants Achieving a Systolic Blood Pressure Reduction of at Least 5 mmHgTime frame: Baseline and Month 12 (days 335-364)
  • AddedProportion of Participants Achieving Home Blood Pressure Control Below 135/85 mmHgTime frame: Month 12 (days 335-364)
  • AddedProportion of Participants Achieving Home Blood Pressure Control Below 140/90 mmHgTime frame: Month 12 (days 335-364)
  • AddedWithin-Session Change in Home Systolic Blood PressureTime frame: Throughout the 12-month intervention period
  • RemovedConcentration of RenalaseTime frame: 3 months
  • RemovedConcentration of catecholamineTime frame: 3 months
  • RemovedConcentration of adenosineTime frame: 3 months
  • RemovedConcentration of bradykininTime frame: 3 months
  • RemovedConcentration of reninTime frame: 3 months
Nov 10, 2026
Title
Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    4 sites added
    Show 4 added (4 China)
    • Anyang District Hospital · Anyang, China
    • Huaihe Hospital of Henan University · Kaifeng, China
    • Yongcheng Central Hospital · Shangqiu, China
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    Start date Jul 3, 2021→Sep 1, 2023
    Primary completion Dec 1, 2026→Aug 31, 2025 (now actual)
    Study completion Dec 1, 2030→Jan 1, 2026 (now actual)
    Enrollment 400 (estimated)→600 (actual)
    Eligibility Criteria largely rewritten (23 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedDiagnosed patients with mild hypertension (SBP: 140~159mmHg; DBP: 90~99mmHg)
    • AddedAdults aged 18-80 years.
    • AddedDiagnosis of essential hypertension according to established clinical guidelines, with a mean screening home systolic blood pressure (SBP) of 135-179 mmHg and a mean home diastolic blood pressure (DBP) below 105 mmHg.
    • AddedParticipants who were either untreated or receiving antihypertensive medication with inadequately controlled blood pressure. For participants receiving antihypertensive medication, drug classes and doses had to remain stable for at least 4 weeks before enrollment, with no planned active adjustment during the study.
    • AddedCompletion of at least 2 weeks of twice-daily home blood pressure monitoring during screening, with the mean home SBP remaining within 135-179 mmHg before randomization.
    • AddedAbility and willingness to perform twice-daily home blood pressure monitoring and complete the 12-month intervention and follow-up.
    • AddedProvision of written informed consent.
    Exclusion criteria
    • RemovedCannot tolerate RIPC
    • RemovedNon-essential hypertension
    • Removedpatients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance
    • Removedpatients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
    • AddedSecondary hypertension of any cause or incomplete screening for secondary causes of hypertension.
    • AddedCardiovascular or cerebrovascular events within 6 months before enrollment.
    • AddedClinically significant arrhythmias, including atrial fibrillation or frequent ventricular premature beats, that could interfere with automated blood pressure measurement.
    • AddedPeripheral vascular disease, severe upper-limb vascular insufficiency, or conditions precluding safe cuff inflation, including an arteriovenous fistula in the measurement arm, lymphedema, skin lesions, or upper-limb surgery within the preceding 3 months.
    • AddedOrthostatic hypotension, defined as a systolic blood pressure decrease of at least 20 mmHg on standing or symptomatic orthostatic hypotension.
    • AddedInter-arm systolic blood pressure difference greater than 15 mmHg.
    • AddedSevere target-organ damage, including estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², left ventricular ejection fraction (LVEF) below 40%, or New York Heart Association (NYHA) functional class III-IV.
    • AddedPoorly controlled diabetes mellitus (HbA1c ≥9.0%) or established diabetic autonomic neuropathy.
    • AddedPregnancy, planned pregnancy, or lactation.
    • AddedParticipation in another interventional clinical trial within 30 days before enrollment.
    • AddedInability to comply with the study protocol because of cognitive impairment, severe psychiatric disorders, or logistical difficulties with follow-up.
    • AddedConfirmed mean screening home DBP ≥105 mmHg on repeat measurement.
    Primary outcomes 1 added, 2 removed
    What changed in the outcomes
    • AddedChange From Baseline in Home Systolic Blood Pressure at 12 MonthsTime frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)
    • RemovedMean systolic blood pressureTime frame: 3 months
    • RemovedMean diastolic blood pressureTime frame: 3 months
    Secondary outcomes 6 added, 5 removed
    What changed in the outcomes
    • AddedChange From Baseline in Home Diastolic Blood Pressure at 12 MonthsTime frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364)
    • AddedChange From Baseline in Home Systolic Blood Pressure at Months 1, 3, 6, and 9Time frame: Baseline and Days 30, 90, 180, and 270 after randomization
    • AddedProportion of Participants Achieving a Systolic Blood Pressure Reduction of at Least 5 mmHgTime frame: Baseline and Month 12 (days 335-364)
    • AddedProportion of Participants Achieving Home Blood Pressure Control Below 135/85 mmHgTime frame: Month 12 (days 335-364)
    • AddedProportion of Participants Achieving Home Blood Pressure Control Below 140/90 mmHgTime frame: Month 12 (days 335-364)
    • AddedWithin-Session Change in Home Systolic Blood PressureTime frame: Throughout the 12-month intervention period
    • RemovedConcentration of RenalaseTime frame: 3 months
    • RemovedConcentration of catecholamineTime frame: 3 months
    • RemovedConcentration of adenosineTime frame: 3 months
    • RemovedConcentration of bradykininTime frame: 3 months
    • RemovedConcentration of reninTime frame: 3 months
    Title Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension
    + 5 other changes: verification date, description, design details, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04753840
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Sep 1, 2023
Primary completion
Aug 31, 2025
Completion
Jan 1, 2026
Last update
Nov 10, 2026

Study contacts

Muwei Li, MD
study chair · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion